Developing innovative new ways to treat diseases in people and animals.
|HylaPharm is a university spinout company developing cancer chemotherapies targeted for potentially deadly, locally advanced cancers that affect nearly 200,000 Americans each year. Unlike conventional chemotherapy that enters vein and diffuses all over the body before getting to the tumor, our patented drug HylaPlat™ is injected into tumor or surrounding at-risk tissues. This results in very high tumor dosing. HylaPlat™ then drains into local lymph nodes, which is where tumors generally metastasize first. Our technology makes treatment of certain types of cancer, including breast cancer and head and neck cancer, both safer and more effective in animal trials. HylaPlat™ has already shown efficacy in multiple mouse models, and in several dogs with large, naturally occurring cancers. HylaPlat™ works by complexing conventional chemotherapy with nano-sized Hyaluronan, a natural compound in the body that cancers seek and bind.HylaPlat’s™ development path may be shorter because its initial target is an “orphan disease,” and because it is a novel complex of already approved drugs. The Kansas BioScience Authority has funded our upcoming FDA Investigational New Drug–enabling animal trials. Our team is based out of incubator space in Lawrence, Kansas.9/17/2015 HylaPharm has received an SBIR contract from the National Cancer Institute (division of National Institutes of Health) to develop NanoTor (hyaluronan rapamycin nano conjugates) for treatment of breast cancer.09/03/2015 – HylaPharm has received a Minor Use and Minor Species fee waiver from the FDA for the development of HylaPlat for the treatment of squamous cell carcinomas in dogs.|